Choi, Wonyoung Lee, Wonyeop Kim, Youngwook Lee, Sang-Jin Lee, Geon Kook Park, Seung-Jin Ju, Sinyeong Kim, Seon-Young Lee, Cheolju Han, Ji-Youn 2025-04-25T08:02:22Z 2025-04-25T08:02:22Z 2025-04-25 2025-03 0169-5002 https://pubs.kist.re.kr/handle/201004/152351 Background: Never-smoker lung adenocarcinoma (NSLA) exhibits distinct immunosuppressive profiles and a lower tumor mutation burden compared with lung adenocarcinoma in smokers. These correlate with poor responses to immune checkpoint inhibitors. In this study, we aimed to elucidate the tumor-immune microenvironment of NSLA without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alterations and identify novel therapeutic targets. Methods: We analyzed genome, transcriptome, and proteomic data from 102 NSLA tumor samples and 16 normal adjacent tissues. We classified tumors into distinct immune clusters (IC) based on gene signatures by profiling the tumor-infiltrating immune cells. Results: The tumors were stratified into three ICs: hot, intermediate, and cold. Notably, only 21 (20.6%) patients exhibited hot IC enriched in cytotoxic T cells, natural killer cells, and B-cell signatures, which correlated with improved recurrence-free survival. Cold ICs (37.3%) exhibited higher myeloid-derived suppressor cell (MDSC) levels and M2 macrophage signatures, with poor immune cell infiltration and relatively low stimulatory cytokines and chemokines expression. CEACAM1, and NECTIN2 were upregulated in intermediate and cold ICs and correlated with MDSC and M2 macrophage infiltration. High expression of these genes was associated with poor survival outcomes. Protein-protein network analysis of 20 upregulated molecules associated with cancer- and driver-related proteins in cold IC identified XPO 1 as a key component. Conclusion: Our proteogenomic analysis highlighted the immunosuppressive properties of NSLA without EGFR and ALK alterations and identified novel therapeutic targets. These findings may provide novel treatment strategies that could improve the clinical outcomes of patients with NSLA. English Elsevier BV Immune landscape and novel therapeutic targets of epidermal growth factor receptor and anaplastic lymphoma kinase wild type never-smoker lung adenocarcinoma Article 10.1016/j.lungcan.2025.108448 1 Lung Cancer, v.201 Lung Cancer 201 N scie scopus 001429224600001 2-s2.0-85217949682 Oncology Respiratory System Oncology Respiratory System Article CANCER PROTEOGENOMICS MUTATIONS REVEAL EGFR Never-smoker Lung adenocarcinoma Tumor-immune microenvironment